Long-term subfoveal choroidal thickness changes following half-dose photodynamic therapy (PDT) in eyes with chronic central serous chorioretinopathy.

<p>After PDT, baseline subfoveal choroidal thickness significantly decreased at each visit in the successful group and at 1, 3, 24, and 36 months in the unsuccessful group. All values are presented as mean ± standard error of the mean. *<i>P</i> < 0.05, **<i>P</i> < 0.01, ***<i>P</i> < 0.001.</p

Comparison of baseline clinical characteristics according to success of half-dose PDT.

<p>Comparison of baseline clinical characteristics according to success of half-dose PDT.</p

Long-term visual acuity changes following half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.

<p>Baseline best-corrected visual acuity (BCVA) significantly improved after 3, 6, 12, 24, and 36 months in the successful group and at 24 and 36 months in the unsuccessful group. All values are presented as mean ± standard error of the mean. *<i>P</i> < 0.05.</p

Additional file 1 of The parthenocarpic gene Pat-k is generated by a natural mutation of SlAGL6 affecting fruit development in tomato (Solanum lycopersicum L.)

Table S1. Raw data status of whole genome re-sequencing of ‘MPK-1’. Table S2. Primer sequences used for fine mapping. Table S3. Primer sequences used for primer walking of the insertion in the Solyc01g093960 gene. Table S4. Primer sequences used for quantitative RT-PCR analysis of the Solyc01g093960 gene. Table S5. The information of SNPs used in QTL analysis in this study. Table S6. The information of SNPs for fine mapping of Pat-k in this study. Figure S1. Amplification products produced by the primers of 093960_fwd and 093960_rev. (XLSX 136 kb

Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study

<div><p>Polypoidal choroidal vasculopathy (PCV) is characterized by polyp-like choroidal neovascularization and a branching vascular network. Intravitreal aflibercept injection (IAI) or photodynamic therapy (PDT) is used for treatment. We retrospectively compared the 1-year outcomes of IAI monotherapy and its combination with initial PDT for PCV. Twelve eyes with naïve PCV received three IAIs and a single PDT after the first IAI and as needed injection (combination group); 11 eyes with naïve PCV received three IAIs and as needed injections (IAI group). Significant improvements in visual acuity after 2 months and in CRT after 1 month were maintained at 12 months in both groups (both <i>P</i> < 0.05); groups did not differ significantly at any time point. CCT significantly reduced after 3 and 12 months in the combination group (both <i>P</i> < 0.05) but not in the IAI group. A mean of 3.7 ± 0.9 and 5.6 ± 2.0 injections was administered to the combination and IAI groups, respectively (<i>P</i> = 0.013). Within a 1-year period, combination therapy was found to yield similar visual acuity and retinal structure improvements and maintenance as IAI monotherapy while requiring fewer IAIs.</p></div

Changes in best-corrected visual acuity at 3, 6, 9, and 12 months in the two study groups.

<p>Visual acuity improvements were maintained at 12 months in both groups, and no significant inter-group differences were observed at any time point.</p

Outcomes of central retinal thickness and central choroidal thickness.

<p>Outcomes of central retinal thickness and central choroidal thickness.</p

Numbers of intravitreal aflibercept injections (IAI) administered to the two study groups.

<p><b>(A)</b> Significantly fewer IAIs were administered to the combination group than to the IAI group. <b>(B)</b> The groups had no significant difference in terms of the percentage of cases over 12 months. * <i>P</i> < 0.05 by Mann–Whitney <i>U</i> test.</p

Patient characteristics.

<p>Patient characteristics.</p

Central retinal thickness (CRT) and central choroidal thickness (CCT) outcomes in the two study groups.

<p><b>(A)</b> Reductions in CRT were maintained at 12 months after both treatments, and no significant differences were observed between the groups at any time point during the 12-month study period. <b>(B)</b> A significant reduction in CCT from baseline to 3 and 12 months was observed in the combination group. No significant differences were observed between the two groups at any time point. * <i>P</i> < 0.05, ** <i>P</i> < 0.01 by Repeated measures ANOVA.</p